Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Martin Zimmermann

Showing results (181-190 of 279) with videos related to

Pageof 28
Sort By:
British Journal of Haematology|February 26, 2016
Implications of delayed bone marrow aspirations at the end of treatment induction for risk stratification and outcome in children with acute lymphoblastic leukaemiaJan Zuna, Anja Moericke, Mari Arens, et al.
Cancer Causes & Control : CCC|August 2, 2023
Subsequent primary neoplasms after childhood cancer therapy - design and description of the German nested case-control study STATT-SCARPeter Scholz-Kreisel, Cornelia Becker, Melanie Kaiser, et al.
Genes, Chromosomes & Cancer|July 22, 2014
Recurrent RHOA mutations in pediatric Burkitt lymphoma treated according to the NHL-BFM protocolsMarius Rohde, Julia Richter, Matthias Schlesner, et al.
British Journal of Haematology|January 27, 2024
Variant ALK-fusion positive anaplastic large cell lymphoma (ALCL): A population-based paediatric study of the NHL-BFM study groupJette Luedersen, Udo Zur Stadt, Julia Richter, et al.
JNCI Cancer Spectrum|July 31, 2019
Validation of Minimal Residual Disease as Surrogate Endpoint for Event-Free Survival in Childhood Acute Lymphoblastic LeukemiaStefania Galimberti, Meenakshi Devidas, Ausiliatrice Lucenti, et al.
Blood Advances|November 26, 2019
Results of CoALL 07-03 study childhood ALL based on combined risk assessment by in vivo and in vitro pharmacosensitivityFranziska Schramm, Udo Zur Stadt, Martin Zimmermann, et al.
Haematologica|December 10, 2020
Pre-existing antibodies against polyethylene glycol reduce asparaginase activities on first administration of pegylated E. coli asparaginase in children with acute lymphocytic leukemiaAlaeddin Khalil, Gudrun Würthwein, Jana Golitsch, et al.
Proceedings of the National Academy of Sciences of the United States of America|August 14, 2008
Cloning of genes involved in chromosomal translocations by high-resolution single nucleotide polymorphism genomic microarrayNorihiko Kawamata, Seishi Ogawa, Martin Zimmermann, et al.
Hemasphere|June 5, 2023
Incidence and Characteristics of Hypersensitivity Reactions to PEG-asparaginase Observed in 6136 Children With Acute Lymphoblastic Leukemia Enrolled in the AIEOP-BFM ALL 2009 Study ProtocolCarmelo Rizzari, Anja Möricke, Maria Grazia Valsecchi, et al.
The American Journal of Surgical Pathology|April 1, 2011
Diagnosis and immunophenotype of 188 pediatric lymphoblastic lymphomas treated within a randomized prospective trial: experiences and preliminary recommendations from the European childhood lymphoma pathology panelIlske Oschlies, Birgit Burkhardt, Catherine Chassagne-Clement, et al.
Pageof 28

Showing results (181-190 of 279) with videos related to

Sort By:
Pageof 28
British Journal of Haematology|February 26, 2016
Implications of delayed bone marrow aspirations at the end of treatment induction for risk stratification and outcome in children with acute lymphoblastic leukaemiaJan Zuna, Anja Moericke, Mari Arens, et al.
Cancer Causes & Control : CCC|August 2, 2023
Subsequent primary neoplasms after childhood cancer therapy - design and description of the German nested case-control study STATT-SCARPeter Scholz-Kreisel, Cornelia Becker, Melanie Kaiser, et al.
Genes, Chromosomes & Cancer|July 22, 2014
Recurrent RHOA mutations in pediatric Burkitt lymphoma treated according to the NHL-BFM protocolsMarius Rohde, Julia Richter, Matthias Schlesner, et al.
British Journal of Haematology|January 27, 2024
Variant ALK-fusion positive anaplastic large cell lymphoma (ALCL): A population-based paediatric study of the NHL-BFM study groupJette Luedersen, Udo Zur Stadt, Julia Richter, et al.
JNCI Cancer Spectrum|July 31, 2019
Validation of Minimal Residual Disease as Surrogate Endpoint for Event-Free Survival in Childhood Acute Lymphoblastic LeukemiaStefania Galimberti, Meenakshi Devidas, Ausiliatrice Lucenti, et al.
Blood Advances|November 26, 2019
Results of CoALL 07-03 study childhood ALL based on combined risk assessment by in vivo and in vitro pharmacosensitivityFranziska Schramm, Udo Zur Stadt, Martin Zimmermann, et al.
Haematologica|December 10, 2020
Pre-existing antibodies against polyethylene glycol reduce asparaginase activities on first administration of pegylated E. coli asparaginase in children with acute lymphocytic leukemiaAlaeddin Khalil, Gudrun Würthwein, Jana Golitsch, et al.
Proceedings of the National Academy of Sciences of the United States of America|August 14, 2008
Cloning of genes involved in chromosomal translocations by high-resolution single nucleotide polymorphism genomic microarrayNorihiko Kawamata, Seishi Ogawa, Martin Zimmermann, et al.
Hemasphere|June 5, 2023
Incidence and Characteristics of Hypersensitivity Reactions to PEG-asparaginase Observed in 6136 Children With Acute Lymphoblastic Leukemia Enrolled in the AIEOP-BFM ALL 2009 Study ProtocolCarmelo Rizzari, Anja Möricke, Maria Grazia Valsecchi, et al.
The American Journal of Surgical Pathology|April 1, 2011
Diagnosis and immunophenotype of 188 pediatric lymphoblastic lymphomas treated within a randomized prospective trial: experiences and preliminary recommendations from the European childhood lymphoma pathology panelIlske Oschlies, Birgit Burkhardt, Catherine Chassagne-Clement, et al.
Pageof 28